Sylvester Comprehensive Cancer Center

  • MAPS - Abramowitz, Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:

    IRB: 20101056

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase III Randomized Trial of MRIMapped DoseEscalated Salvage Radiotherapy PostProstatectomy: The MAPS Trial

    Eligibility Criteria - NCT01411345 *This information has been extracted from " www.clinicaltrials.gov"

  • HEAT - Abramowitz, Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:
    RCemailImg Jacqueline Rodriguez Amado
    RCphone 3052435620

    IRB: 20110491

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: PROSTATE CANCER FOUNDATION

    Enrolling Sites:

    Deerfield
    Gables
    Northern Sydney Local Health District
    Sylvester
    University Hospital Trust of Turin

    Title:

    A Randomized Study of Radiation Hypofractionation via Extended versus Accelerated Therapy (HEAT) For Prostate Cancer

    Eligibility Criteria - NCT01794403 *This information has been extracted from " www.clinicaltrials.gov"

  • NRG-GU002 - Abramowitz, Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:
    RCemailImg Pavel Noa Hechavarria

    IRB: 20170414

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    NRG-GU002: PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL

    Eligibility Criteria - NCT03070886 *This information has been extracted from " www.clinicaltrials.gov"

  • 42756493BLC3001 - Benedetto, Pasquale

  • Investigator:
    Pasquale Benedetto
    RCname Email

    Coordinator:

    IRB: 20180387

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder

    Sponsor: Janssen

    Enrolling Sites:

    Sylvester

    Title:

    42756493BLC3001: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

    Eligibility Criteria - NCT03390504 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170004 - Gonzalgo Mark

  • Investigator:
    Mark Gonzalgo
    RCname Email

    Coordinator:
    RCemailImg Rody Barakat
    RCphone 3052432177

    IRB: 20170004

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    Randomized Clinical Trial of Intra-corporal vs Extra-corporal Urinary Diversion after Robot Assisted Radical Cystectomy

    Eligibility Criteria - NCT03469362 *This information has been extracted from " www.clinicaltrials.gov"

  • QUILTT-3.032 - Gonzalgo, Mark

  • Investigator:
    Mark Gonzalgo
    RCname Email

    Coordinator:
    RCemailImg Rody Barakat
    RCphone 3052432177

    IRB: 20170350

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder

    Sponsor: ALTOR BIOSCIENCE CORP

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    CA-ALT-803-01-16: QUILT-3.032 - A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

    Eligibility Criteria - NCT03022825 *This information has been extracted from " www.clinicaltrials.gov"

  • C-610-01 - Hosein, Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20180763

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Breast,Bladder,Rectum,Soft Tissue,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-610-01:A Phase 1a First-in-Human Study of Safety and Tolerability of ASV? AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects with Solid Tumor at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection

    Eligibility Criteria - NCT03673020 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • 1381.2 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190219

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Bladder,Stomach,Lung

    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Sylvester

    Title:

    1381.2: An Open Label, Phase I Dose-Finding Study Of BI 754111 In Combination With BI 754091 In Patients With Advanced Solid Cancers Followed By Expansion Cohorts At The Selected Dose Of The Combination In Patients With Non-Small Cell Lung Cancer And Other Solid Tumors

    Eligibility Criteria - NCT03156114 *This information has been extracted from " www.clinicaltrials.gov"

  • SGN22E-002 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20170918

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Other Urinary

    Sponsor: SEATTLE GENETICS

    Enrolling Sites:

    Sylvester

    Title:

    SGN22E-002: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for thetreatment of urothelial cancer

    Eligibility Criteria - NCT03288545 *This information has been extracted from " www.clinicaltrials.gov"

  • JX594-REN026 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20180055

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Kidney

    Sponsor: SILLAJEN INC

    Enrolling Sites:

    Sylvester

    Title:

    JX594-REN026: A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)

    Eligibility Criteria - NCT03294083 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Colon,Breast-Female,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • PT2977-201 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20180954

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Kidney

    Sponsor: Peloton

    Enrolling Sites:

    Sylvester

    Title:

    PT2977-201 : A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

    Eligibility Criteria - NCT03634540 *This information has been extracted from " www.clinicaltrials.gov"

  • TTX-030-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20181017

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Colon,Pancreas

    Sponsor: TTH

    Enrolling Sites:

    Sylvester

    Title:

    TTX-030-001 : Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy inPatients with Lymphoma or Solid Tumor Malignancies

    Eligibility Criteria - NCT03884556 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-444-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190073

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate,Bladder,Kidney,Liver

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-444-001: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

    Eligibility Criteria - NCT02655822 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170656 - Penedo Frank

  • Investigator:
    Frank Penedo
    RCname Email

    Coordinator:

    IRB: 20170656

    SDG: Population Sciences
    Disease Site(s):

    Prostate

    Sponsor: NCI

    Enrolling Sites:

    Community Clinics
    Deerfield
    Gables
    Hollywood
    Kendall
    NorthWestern University
    Plantation
    Sylvester

    Title:

    Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer

    Eligibility Criteria - NCT03344757 *This information has been extracted from " www.clinicaltrials.gov"

  • The Miami BLaStM Trial - Pollack, Alan

  • Investigator:
    Alan Pollack
    RCname Email

    Coordinator:
    RCemailImg Pavel Noa Hechavarria

    IRB: 20140627

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    JMH
    Sylvester

    Title:

    A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy ? The Miami BLaStM Trial

    Eligibility Criteria - NCT02307058 *This information has been extracted from " www.clinicaltrials.gov"

  • Miami MAST Trial - Punnen, Sanoj

  • Investigator:
    Sanoj Punnen
    RCname Email

    Coordinator:
    RCemailImg Zaida Abreu
    RCphone 3052434243

    IRB: 20140372

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: NIH

    Enrolling Sites:

    Deerfield
    Gables
    JMH
    Kendall
    Plantation
    Sylvester

    Title:

    MRI-Guided Active Selection for Treatment of Prostate Cancer: The Miami MAST Trial

    Eligibility Criteria - NCT02242773 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180363 - Ritch Chad

  • Investigator:
    Chad Ritch
    RCname Email

    Coordinator:
    RCemailImg Rody Barakat
    RCphone 3052432177

    IRB: 20180363

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Other Male Genital,Bladder

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    EA8134: InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)

    Eligibility Criteria - NCT02305654 *This information has been extracted from " www.clinicaltrials.gov"

  • 676-00: KEYNOTE-676 - Ritch, Chad

  • Investigator:
    Chad Ritch
    RCname Email

    Coordinator:
    RCemailImg Rody Barakat
    RCphone 3052432177

    IRB: 20180864

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Sylvester

    Title:

    676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

    Eligibility Criteria - NCT03711032 *This information has been extracted from " www.clinicaltrials.gov"

  • SWOG S1802 - Ritch, Chad

  • Investigator:
    Chad Ritch
    RCname Email

    Coordinator:
    RCemailImg Rody Barakat
    RCphone 3052432177

    IRB: 20180970

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SWOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    S1802: PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER

    Eligibility Criteria - NCT03678025 *This information has been extracted from " www.clinicaltrials.gov"

  • NKRT-214 - Sharma, Janaki

  • Investigator:
    Janaki Sharma
    RCname Email

    Coordinator:

    IRB: 20190795

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Kidney

    Sponsor: Nektar Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

    Eligibility Criteria - NCT03729245 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • DS8201-a-U105 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180855

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Bladder

    Sponsor: DAIICHI SANKYO

    Enrolling Sites:

    Sylvester

    Title:

    DS8201-A-U105:A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

    Eligibility Criteria - NCT03523572 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"